This was a recent article posted on the AstraZeneca China website, on March 23, 2007. it discusses the evolving partnership which is emerging between the pharmaceutical giant and China.
March 23, 2007, Shanghai, China -- AstraZeneca today announced Shanghai's Zhangjiang Hi-Tech Park as the initial base for its new Innovation Centre China (ICC).
The ICC, announced in May 2006 as part of a larger $100 million R&D investment package, is the primary focus of AstraZeneca's latest investment in China. The Centre will focus on the benefit and value of innovative medicines for Chinese patients, initially concentrating on cancer through the development of knowledge about Chinese patients, biomarkers and genetics. The start of construction work at the site is an important milestone in establishing a dedicated AstraZeneca research presence in China and the company's ambitions of having a strong R&D presence in the region.
Jan Lundberg, Executive Vice-President of Discovery at AstraZeneca, said: "This is an important step forward in a high priority project which promises to hold great potential to advance our understanding of a disease which has such devastating consequences. It will be an integral part of our global R&D activity aimed at ensuring that the right patients are treated with our oncology drugs and will take advantage of the excellent science base in Shanghai where there is a burgeoning biotech industry. "
"This milestone is also another powerful example of our of policy of being ‘In China for China'."
The facility will open in mid-2007 and provide a base to build capabilities and skills in China prior to the establishment of a permanent state-of-the-art site. AstraZeneca has already initiated a comprehensive search for a permanent location for the ICC.
To view the entire article at its original location click on the title of this post.
AdMark China is committed to finding for our customers the best possible talent as quickly as possible. Contact us at email@example.com or at +86 21 6288 9292.